Form 8-K - Current report:
SEC Accession No. 0001193125-20-141579
Filing Date
2020-05-13
Accepted
2020-05-13 16:00:39
Documents
12
Period of Report
2020-05-12
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d875918d8k.htm   iXBRL 8-K 35764
  Complete submission text file 0001193125-20-141579.txt   156435

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA apls-20200512.xsd EX-101.SCH 3067
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20200512_lab.xml EX-101.LAB 17374
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20200512_pre.xml EX-101.PRE 10951
11 EXTRACTED XBRL INSTANCE DOCUMENT d875918d8k_htm.xml XML 3208
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

EIN.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 20873123
SIC: 2834 Pharmaceutical Preparations